Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long ... This work provides a systematic study of the solubility, structure, oligomerization, and long-term ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some ...

a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in those without diabetes. These findings suggest that insurance plan type and structure may be a crucial intervention point ...

Yet the soaring enthusiasm for so-called glucagon-like peptide-1 receptor ... Valuation for GLP-1 Manufacturers and Entrants Notes: *Altimmune, Inc., Viking Therapeutics, Structure Therapeutics ...